- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Neuromyelitis optica spectrum disorder (NMOSD)
- Meeting Date: November 2020
- Public Summary Document (PSD) November 2020 PBAC Meeting - (PDF 1423KB)
- Public Summary Document (PSD) November 2020 PBAC Meeting - (Word 220KB)
Eculizumab – November 2020
Eculizumab: Solution concentrate for I.V. infusion 300 mg in 30 mL; Soliris®
Last updated
19 March 2021